Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer ...Middle East

NANJING, China, March 9, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that the first patient has been successfully dosed in a Phase Ⅱ clinical study evaluating Opamtistomig (LBL-024), the company's...

Hence then, the article about leads biolabs opamtistomig lbl 024 enrolls first escc patient exploring dual pd l1 4 1bb mechanism for superior survival benefits in china s high incidence cancer was published today ( Monday 09/03/2026 - 09:29 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer )

Also on site :

• US-Patient mit fortgeschrittenem Lungenkrebs durch neuartige Immuntherapie-Behandlung in China stabilisiert
• Egypt Proposes Forming Joint Arab Defense Force Amid Regional Tensions
• Who is Iran’s new supreme leader Mojtaba Khamenei? Son of Ayatollah Ali Khamenei to take over father’s role